1. 输入关键词后点击检索按钮可查询指定关键词在语料中的对应情况
  2. 选择语种可限定关键词的语言,当前支持中文和英文,默认选择中文
  3. 主题选项中可限定检索语料的文章主题范围,默认全部主题
  4. 主题选项中可限定检索语料的文本类型范围,默认全部类型
  5. 在结果列表中,点击操作栏中的“查看中文全文”或“查看英文全文”按钮可查看该句所在的中文语料全文
句对齐列表 共 16269 个结果  
序号 中文 英文 操作
7991 2018年5月出现了关于这一安全隐患的报道,在博茨瓦纳进行的一项研究发现,在服用度鲁特韦期间怀孕的426名妇女所生婴儿中,有4例神经管缺陷 This potential safety concern was reported in May 2018 from a study in Botswana that found 4 cases of neural tube defects out of 426 women who became pregnant while taking DTG.
7992 基于这些初步研究结果,许多国家建议孕妇和有生育潜力的妇女改用依非韦仑(EFV)。 Based on these preliminary findings, many countries advised pregnant women and women of childbearing potential to take efavirenz (EFV) instead.
7993 两项大型临床试验比较了在非洲使用度鲁特韦依非韦伦的疗效和安全性,所获得的新数据扩大了证据基础。 New data from two large clinical trials comparing the efficacy and safety of DTG and EFV in Africa have now expanded the evidence base.
7994 新证据显示,神经管缺陷风险明显低于最初研究显示的风险水平。 The risks of neural tube defects are significantly lower than what the initial studies may have suggested.
7995 指南小组还审视了与这两种药物相关的益处和危害的数学模型、艾滋病毒感染者的认识和偏好以及在不同国家实施抗艾滋病毒规划的相关因素和费用。 The guidelines group also considered mathematical models of the benefits and harms associated with the two drugs; the values and preferences of people living with HIV, as well as factors related to implementation of HIV programmes in different countries, and cost.
7996 与目前使用的其他药物相比,度鲁特韦较为有效较易服用,而且副作用较少。 DTG is a drug that is more effective, easier to take and has fewer side effects than alternative drugs that are currently used.
7997 另外,度鲁特韦具有很高的耐药基因屏障,鉴于艾滋病毒携带者对依非韦伦和奈韦拉平(nevirapine)治疗方案的耐药性呈上升趋势,这一点很重要。 DTG also has a high genetic barrier to developing drug resistance, which is important given the rising trend of resistance to EFV and nevirapine-based regimens.
7998 2019年,世卫组织调查了18个国家的情况,其中有12个国家报告说治疗前耐药性水平超过了10%的建议阈值。 In 2019, 12 out of 18 countries surveyed by WHO reported pre-treatment drug resistance levels exceeding the recommended threshold of 10%.
7999 上述研究结果为决定更新2019年治疗指南提供了依据 All of above findings informed the decision to update the 2019 guidelines.
8000 2019年,82个低收入和中等收入国家报告称正向使用度鲁特韦艾滋病毒治疗方案过渡。 In 2019, 82 low- and middle-income countries reported to be transitioning to DTG-based HIV treatment regimens.